HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADCM SASDATA 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000011400000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier SUBJID Subject Identifier for the Study SITEID Study Site Identifier &CMSEQ Sequence Number *CMCAT Category for Medication 2CMSCAT Subcategory for Medication A CMSTDTC Start Date/Time of Medication B CMENDTC End Date/Time of Medication LJ CMTRT Reported Name of Drug, Med, or Therapy VL CMDECOD Standardized Medication Name   CMCODE Standardized Medication Code ģ PREFL Pre-treatment Flag ÷ONPERFL On-Period Flag ųONTR01FLOn-Period 01 Flag łONTR02FLOn-Period 02 Flag śASTDT Analysis Start Date DATE ūASTDTF Analysis Start Date Imputation Flag ASTDY Analysis Start Relative Day AENDT Analysis End Date DATE  AENDTF Analysis End Date Imputation Flag AENDY Analysis End Relative Day CMCLAS Medication Class CMCLASCDMedication Class Code 4LDRUGNAMEWHODrug preferred name 9ATC1CD ATC Level 1 Code …?ATC1T ATC Level 1 Text †ATC2CD ATC Level 2 Code Å@ATC2T ATC Level 2 Text ČATC3CD ATC Level 3 Code 'ATC3T ATC Level 3 Text   ATC4CD ATC Level 4 Code 3!ATC4T ATC Level 4 Text 8"ATC5CD ATC Level 5 Code VR#ATC5T ATC Level 5 Text ]$CMSTDY Study Day of Start of Medication Æ%CMENDY Study Day of End of Medication ·&CMDOSE Dose per Administration æ'CMROUTE Route of Administration Ē(CMDOSTXTDose Description Ė)CMDOSU Dose Units Ģ*CMDOSFRQDosing Frequency per Interval Ī+CMENRTPTEnd Relative to Reference Time Point Ń,CMENTPT End Reference Time Point Ų-EPOCH Epoch ī.DICTVER Dictionary Name and Version /AGE Age 0AGEU Age Units 1SEX Sex  2SEXN Sex (N) ! 3RACE Race )4RACEN Race (N) I 5ARACE Analysis Race Q6ARACEN Analysis Race (N) q7SAFFL Safety Population Flag y8ARM Description of Planned Arm z 9ARMCD Planned Arm Code •:ACTARM Description of Actual Arm ž ;ACTARMCDActual Arm Code ¹TRTSDTM Datetime of First Exposure to Treatment DATETIME Ņ?TRTEDT Date of Last Exposure to Treatment DATE Ś@TRTETM Time of Last Exposure to Treatment TIME  āATRTEDTM Datetime of Last Exposure to Treatment DATETIME źBV01DT Date of Unblinding or Visit at 1MPD2 DATE ņCV02DT Date of Unblinding or Visit at 6MPD2 DATE śDV03DT Date of Visit at 1M after Vax3/4 DATE EV04DT Date of Visit at 6M after Vax3/4 DATE  FVAX101DTVaccination Date 01 DATE GVAX10UDTVaccination Date Unplanned DATE HVAX102DTVaccination Date 02 DATE "IVAX201DTVaccination Date 03 DATE *JVAX202DTVaccination Date 04 DATE 2KCOHORTN Cohort Group (N) :LCOHORT Cohort Group BMDOSALVLNActual Dosing Level (N) CNDOSALVL Actual Dosing Level KODOSPLVLNPlanned Dosing Level (N) LPDOSPLVL Planned Dosing Level TQPHASEN Study Phase (N) URPHASE Study Phase ]SUNBLNDDTTreatment Unblinded Date DATE dTDS30KFL Phase 3 30k Subjects Flag lUHIVFL HIV Positive Subjects Flag mVAGETR01 Age at Vaccination 01 n WAGEGR1 Pooled Age Group 1 vXAGEGR1N Pooled Age Group 1 (N)  YAGEGR4 Pooled Age Group 4 ‰ZAGEGR4N Pooled Age Group 4 (N) ”[TR01SDTMDatetime of First Exposure in Period 01 DATETIME œ\TR01EDTMDatetime of Last Exposure in Period 01 DATETIME ¤]TR02SDTMDatetime of First Exposure in Period 02 DATETIME ¬^TR02EDTMDatetime of Last Exposure in Period 02 DATETIME “_TRT01A Actual Treatment for Period 01 ¼`TRT01AN Actual Treatment for Period 01 (N) ×aTRT01P Planned Treatment for Period 01 ßbTRT01PN Planned Treatment for Period 01 (N) ścTRT02A Actual Treatment for Period 02 dTRT02AN Actual Treatment for Period 02 (N) eTRT02P Planned Treatment for Period 02 %fTRT02PN Planned Treatment for Period 02 (N) @$gVAX101 Vaccination 01 H$hVAX102 Vaccination 02 liVAX10U Vaccination Unplanned $jVAX201 Vaccination 03 ‘$kVAX202 Vaccination 04 µlVAX20U Vaccination Unplanned in Period 02 ŁmVAX20UDTVaccination Date Unplanned in Period 02 DATE ŚnDS3KFL FU to 6MPD2 āoRANDFL Randomized Population Flag ć)pVPHASE Vaccine Phase äqVPHASEN Vaccine Phase(N)  rVAXNO CM Occured after Which Vaccination  HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DWØ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV÷D†Hr§(DW D‰HrĀŪDW(DWb..DV÷.DW ... . . A@Phase 3DWcNNAš12-15 YearsA12-15 YearsAHr§(HrĀŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVä Įą. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Įą.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVņDę Hr ń DWD~THr¹•ŌDW%DW‘..DVņ.DW... . . A@Phase 3DW’NNAš12-15 YearsA12-15 YearsAHr ń Hr¹•Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVä Įą. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Įą.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVņDę Hr ń DWD~THr¹•ŌDW%DW‘..DVņ.DW... . . A@Phase 3DW’NNAš12-15 YearsA12-15 YearsAHr ń Hr¹•Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVä Įą. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Įą.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVņDę Hr ń DWD~THr¹•ŌDW%DW‘..DVņ.DW... . . A@Phase 3DW’NNAš12-15 YearsA12-15 YearsAHr ń Hr¹•Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVģ Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Įš.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūDŒ Hr¬u DWD{ HrÅp DW+DW..DVū.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr¬u HrÅp ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVģ Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Įš.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūDŒ Hr¬u DWD{ HrÅp DW+DW..DVū.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr¬u HrÅp ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DVģ Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Įš.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūDŒ Hr¬u DWD{ HrÅp DW+DW..DVū.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr¬u HrÅp ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006A VACCINATIONS 2021-05-13 Pfizer COVID VACCINE TOZINAMERAN 15268625001 YY DW B“. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B“.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūDŒ Hr¬u DWD{ HrÅp DW+DW..DVū.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr¬u HrÅp ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1006 10061287100612871006AVACCINATIONS 2021-05-14 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DWŽ B‘. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‘.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVžDāąHr°æąDWD÷ųHrĢ„xDW/DW..DVž.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr°æąHrĢ„x..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B+.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV’DĆHr±ń€DWD‚ČHrĶ`ČDW1DWŒ..DV’.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr±ń€HrĶ`Č..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B+.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV’DĆHr±ń€DWD‚ČHrĶ`ČDW1DWŒ..DV’.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr±ń€HrĶ`Č..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B+.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV’DĆHr±ń€DWD‚ČHrĶ`ČDW1DWŒ..DV’.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr±ń€HrĶ`Č..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DVŃ B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B.. VACCINATION WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀD¶HrayDVóDœHr”ŽDWDW‹..DVĀ.DVó... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrayHr”Ž..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DVŃ B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B.. VACCINATION WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀD¶HrayDVóDœHr”ŽDWDW‹..DVĀ.DVó... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrayHr”Ž..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DVŃ B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B.. VACCINATION WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀD¶HrayDVóDœHr”ŽDWDW‹..DVĀ.DVó... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrayHr”Ž..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007A VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ Bį. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bį.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀD¶HrayDVóDœHr”ŽDWDW‹..DVĀ.DVó... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrayHr”Ž..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071415100714151007A0VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW BĢ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĢ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀD¶HrayDVóDœHr”ŽDWDW‹..DVĀ.DVó... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrayHr”Ž..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DVÆ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĀD¾PHraPDV×D°ōHr}#tDVóDW?..DVĀ.DV×... . . A@Phase 3DW@NNAš12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DVÆ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĀD¾PHraPDV×D°ōHr}#tDVóDW?..DVĀ.DV×... . . A@Phase 3DW@NNAš12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DVÆ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĀD¾PHraPDV×D°ōHr}#tDVóDW?..DVĀ.DV×... . . A@Phase 3DW@NNAš12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071428100714281007AVACCINATIONS 2021-05-15 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW BĪ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĪ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVĀDå°HraØ°DV×DēHr}Y˜DV÷DWŠ..DVĀ.DV×... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHraØ°Hr}Y˜..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071428100714281007A VACCINATIONS 2021-06-05 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW¤ Bć. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bć.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVĀDå°HraØ°DV×DēHr}Y˜DV÷DWŠ..DVĀ.DV×... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHraØ°Hr}Y˜..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV§ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDčųHra«ųDV×Dź`Hr}\ąDVóDWŠ..DVĀ.DV×... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHra«ųHr}\ą..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV§ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDčųHra«ųDV×Dź`Hr}\ąDVóDWŠ..DVĀ.DV×... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHra«ųHr}\ą..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV§ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDčųHra«ųDV×Dź`Hr}\ąDVóDWŠ..DVĀ.DV×... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHra«ųHr}\ą..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007A VACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW BĢ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĢ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDčųHra«ųDV×Dź`Hr}\ąDVóDWŠ..DVĀ.DV×... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHra«ųHr}\ą..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071429100714291007A0VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ Bį. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bį.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDčųHra«ųDV×Dź`Hr}\ąDVóDWŠ..DVĀ.DV×... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHra«ųHr}\ą..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071492100714921007AVACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B¤. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¤.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVźDō8Hr–s8DVžDŻ|Hr°ŗ|DWDW‹..DVź.DVž... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr–s8Hr°ŗ|..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071492100714921007A VACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ B¹. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¹.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVźDō8Hr–s8DVžDŻ|Hr°ŗ|DWDW‹..DVź.DVž... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr–s8Hr°ŗ|..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071499100714991007AVACCINATIONS 2021-06-04 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW£ Bø. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bø.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVģDåģHr™ģDV’D×(Hr²ØDWDW‹..DVģ.DV’... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr™ģHr²Ø..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071499100714991007A VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B¢. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¢.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVģDåģHr™ģDV’D×(Hr²ØDWDW‹..DVģ.DV’... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr™ģHr²Ø..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071515100715151007AVACCINATIONS 2021-05-14 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DWŽ Bž. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bž.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVńDŠHHrŸCČDWDčHrŗųčDW"DW‹..DVń.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrŸCČHrŗųč..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071515100715151007A VACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¤ B“. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B“.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVńDŠHHrŸCČDWDčHrŗųčDW"DW‹..DVń.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrŸCČHrŗųč..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071528100715281007AVACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW Bœ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bœ.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņD‡šHr ’šDWDæ@Hr¼yĄDW#DW‹..DVņ.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr ’šHr¼yĄ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071528100715281007A VACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ B±. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B±.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņD‡šHr ’šDWDæ@Hr¼yĄDW#DW‹..DVņ.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr ’šHr¼yĄ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWÓ Bā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated Bā.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŲTHr ćTDW¶DĖ¬Hs£<¬DW#DW‹DWŅDXsDVņ.DWDW”DW¶. . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr ćTHr¼…Hs‡Œ“Hs£<¬Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071543100715431007AVACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ B±. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B±.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDš<Hr ū<DWDĘHHr¼€ČDW#DWŒ..DVņ.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr ū<Hr¼€Č..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071543100715431007A VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW Bœ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bœ.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDš<Hr ū<DWDĘHHr¼€ČDW#DWŒ..DVņ.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr ū<Hr¼€Č..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071554100715541007AVACCINATIONS 2021-06-17 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW° B¾. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¾.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVóDķäHr¢JdDWDŁ¼Hr¼”<DW$DW‹..DVó.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr¢JdHr¼”<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071554100715541007A VACCINATIONS 2021-05-22 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW– B¤. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¤.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVóDķäHr¢JdDWDŁ¼Hr¼”<DW$DW‹..DVó.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr¢JdHr¼”<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071573100715731007AVACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ B«. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B«.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVųDņXHrØęXDW DÕüHrĆ'üDW*DW‹..DVų.DW ... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrØęXHrĆ'ü..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071593100715931007AVACCINATIONS 2021-01-21 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD¶Hr¹ĶœDWD¶Hr¹ĶœDW2DW2..DW..... . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHr¹ĶœHr¹Ķœ..Placebo APlacebo A . .Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071601100716011007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B‰. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‰.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDķØHrŗ(DWDŚ4HrÖņ“DWSDW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrŗ(HrÖņ“..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071603100716031007AVACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¤ BŸ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŸ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDŽ€Hrŗ÷€DWDėŒHr× DW>DWŒ..DW.DW... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrŗ÷€Hr× ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071604100716041007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW Bˆ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bˆ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD‡šHrŗššDWDé¬Hr×,DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrŗššHr×,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071604100716041007A VACCINATIONS 2021-06-12 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW« B¦. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¦.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD‡šHrŗššDWDé¬Hr×,DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrŗššHr×,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071618100716181007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW Bˆ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bˆ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDņHr»[DWD„0Hr֜°DW?DW‹..DW.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr»[Hr֜°..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071618100716181007A VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW¢ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDņHr»[DWD„0Hr֜°DW?DW‹..DW.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr»[Hr֜°..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071635100716351007AVACCINATIONS 2021-05-12 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DWŒ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŽ¼HrĀą¼DW!DÅŠHrŽĒPDW=DW‹..DW .DW!... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHrĀą¼HrŽĒP..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071654100716541007AVACCINATIONS 2021-05-17 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW‘ B…. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B….. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DČ(HrÄkØDW"DĻäHrą"äDW>DW‹..DW .DW"... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÄkØHrą"ä..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDWæ B². .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF03poliomyelitis, trivalent, inactivated, whole virus B².. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD†ÄHrÅ{ÄDW¦DāhHsŽ;hDW?DW‹DWĆDXcDW.DW#DW‘DW¦. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDWæ B². .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF04poliomyelitis oral, bivalent, live attenuated B².. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD†ÄHrÅ{ÄDW¦DāhHsŽ;hDW?DW‹DWĆDXcDW.DW#DW‘DW¦. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDWæ B². .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF02poliomyelitis oral, trivalent, live attenuated B².. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD†ÄHrÅ{ÄDW¦DāhHsŽ;hDW?DW‹DWĆDXcDW.DW#DW‘DW¦. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDWæ B². .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF01poliomyelitis oral, monovalent, live attenuated B².. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD†ÄHrÅ{ÄDW¦DāhHsŽ;hDW?DW‹DWĆDXcDW.DW#DW‘DW¦. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071662100716621007AVACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW¤ B–. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B–.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDā¤HrĒ)$DW$D†LHrā|LDW@DWŒ..DW.DW$... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrĒ)$Hrā|L..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW› B±. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVėDŌHr—¤œDWD”ŌHr³ŌDW!DW‹..DVė.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr—¤œHr³Ō..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081769100817691008AVACCINATIONS 2021-06-03 menactra prophylaxis 0.5 mL intramuscular route once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW¢ B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB².. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVńDŌŠHrŸŽPDWD•ÄHrŗžÄDW>DWu..DVń.DW... . . A@Phase 3DWvNNAš12-15 YearsA12-15 YearsAHrŸŽPHrŗžÄ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DVŪ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŅ<Hr Ż<DW±DĶČHsœ§HDW$DW‹DWĶDXnDVņ.DWDW•DW±. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr Ż<Hr¹ĄøHswø Hsœ§HPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DVŪ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŅ<Hr Ż<DW±DĶČHsœ§HDW$DW‹DWĶDXnDVņ.DWDW•DW±. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr Ż<Hr¹ĄøHswø Hsœ§HPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DVŪ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDŅ<Hr Ż<DW±DĶČHsœ§HDW$DW‹DWĶDXnDVņ.DWDW•DW±. . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr Ż<Hr¹ĄøHswø Hsœ§HPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B].. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷DŹHr§lˆDW¢DŗHsˆĶDW)DW‹DW¾DX_DV÷.DW DWDW¢. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr§lˆHrĀ÷xHsläąHsˆĶPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B].. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷DŹHr§lˆDW¢DŗHsˆĶDW)DW‹DW¾DX_DV÷.DW DWDW¢. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr§lˆHrĀ÷xHsläąHsˆĶPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B].. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷DŹHr§lˆDW¢DŗHsˆĶDW)DW‹DW¾DX_DV÷.DW DWDW¢. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr§lˆHrĀ÷xHsläąHsˆĶPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVūDŲHr¬Ą˜DW©D„äHs‘ŅdDW,DWŒDWÅDXfDVū.DWDW”DW©. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr¬Ą˜HrČh˜Hsv]øHs‘ŅdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVūDŲHr¬Ą˜DW©D„äHs‘ŅdDW,DWŒDWÅDXfDVū.DWDW”DW©. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr¬Ą˜HrČh˜Hsv]øHs‘ŅdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVūDŲHr¬Ą˜DW©D„äHs‘ŅdDW,DWŒDWÅDXfDVū.DWDW”DW©. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr¬Ą˜HrČh˜Hsv]øHs‘ŅdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AŠYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūD×dHr¬æäDWDŃHrČiDW,DW‹..DVū.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr¬æäHrČi..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AŠYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūD×dHr¬æäDWDŃHrČiDW,DW‹..DVū.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr¬æäHrČi..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AŠYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVūD×dHr¬æäDWDŃHrČiDW,DW‹..DVū.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHr¬æäHrČi..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081837100818371008AVACCINATIONS 2021-03-17 Gardasil #2 prophylaxis 0.5 ml intramuscular once HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DWT BV. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BV.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV’DÜPHr² ŠDWØDĮŌHs½ŌDW3DW‹DWÄDXeDV’.DWDW“DWØ. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr² ŠHrĶ·DHsuPHs½ŌPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW½ B¾. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B¾.. OPEN LABEL TREATMENTWHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD£\Hr³#\DW£DØ HsŠ ŒDW9DW‹DWæDX`DW.DWDWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr³#\HrŠ5xHsnz”HsŠ ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW½ B¾. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B¾.. OPEN LABEL TREATMENTWHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD£\Hr³#\DW£DØ HsŠ ŒDW9DW‹DWæDX`DW.DWDWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr³#\HrŠ5xHsnz”HsŠ ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW½ B¾. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B¾.. OPEN LABEL TREATMENTWHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD£\Hr³#\DW£DØ HsŠ ŒDW9DW‹DWæDX`DW.DWDWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr³#\HrŠ5xHsnz”HsŠ ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081872100818721008AVACCINATIONS 2021-03-19 Menactra prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DWV BP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBP.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD€Hr¼XDW~DŠŌHsYmŌDW:DWhDW DX;DW.DWDWkDW~. . . A@Phase 3DWiNNAš12-15 YearsA12-15 YearsAHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081872100818721008A VACCINATIONS 2021-03-19 Trumenba prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE B RFHBPA/FHBPB 06559313001 YY DWV BP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBPA/FHBPB JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine BP.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD€Hr¼XDW~DŠŌHsYmŌDW:DWhDW DX;DW.DWDWkDW~. . . A@Phase 3DWiNNAš12-15 YearsA12-15 YearsAHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081878100818781008AVACCINATIONS 2021-06-29 immunoglobulin prophylaxis once-dose, units and route unknown IMMUNOGLOBULINS NOS 07494701001 YY DW¼ B¶. . IMMUNOGLOBULINS NOS JANTIINFECTIVES FOR SYSTEMIC USE J06IMMUNE SERA AND IMMUNOGLOBULINS J06BIMMUNOGLOBULINS B¶.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĪøHr¼‰8DWDĢ$HrŲ6$DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¼‰8HrŲ6$..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A VACCINATIONS 2021-06-26 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW¹ B³. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B³.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĪøHr¼‰8DWDĢ$HrŲ6$DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¼‰8HrŲ6$..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A0VACCINATIONS 2021-06-29 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW¼ B¶. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B¶.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĪøHr¼‰8DWDĢ$HrŲ6$DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¼‰8HrŲ6$..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A@VACCINATIONS 2021-07-03 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DWĄ Bŗ. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus Bŗ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĪøHr¼‰8DWDĢ$HrŲ6$DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¼‰8HrŲ6$..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008APVACCINATIONS 2021-07-11 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DWČ BĀ. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus BĀ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĪøHr¼‰8DWDĢ$HrŲ6$DW8DW‹..DW.DW... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¼‰8HrŲ6$..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081879100818791008AVACCINATIONS 2021-05-21 PFIZER COVID 19 VACCINE TOZINAMERAN 15268625001 YY DW• B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDĻäHr¼ŠdDWD—ąHrŲąDW8DW‹..DW.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr¼ŠdHrŲą..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081879100818791008A VACCINATIONS 2021-06-12 PFIZER COVID VACCINE TOZINAMERAN 15268625001 YY DW« B„. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B„.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDĻäHr¼ŠdDWD—ąHrŲąDW8DW‹..DW.DW... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHr¼ŠdHrŲą..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008A VACCINATIONS 2021-04-14 tetanus vaccination prophylaxis intramuscular 0.5 ml once TETANUS VACCINE 01594701001 Y YDWp Bd. .TETANUS VACCINES J07AMTETANUS VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AMTETANUS VACCINES J07AM01tetanus toxoid Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠ˜HrÄtDWKDÅXHs%ŲDW2DW2DWgDWūDW .DW"DW6DWK. . . A@Phase 3DW3NNAš12-15 YearsA12-15 YearsAHrÄtHrą$LHrśK8Hs%ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DWĢ Bæ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008A VACCINATIONS 2021-07-15 t-dap vaccine prophylaxis 0.5 mL intramuscular once DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DWĢ Bæ. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids Bæ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŚ4HrÅĻ4DW$DÓ,HrāÉ,DWADW‹..DW.DW$... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÅĻ4HrāÉ,..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B#.. VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD˜HrČ0DW£D§XHsŠ ŲDWADW‹DWĆDX`DW.DW%DWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrČ0HrćÓlHsnHØHsŠ ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B#.. VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD˜HrČ0DW£D§XHsŠ ŲDWADW‹DWĆDX`DW.DW%DWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrČ0HrćÓlHsnHØHsŠ ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B#.. VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD˜HrČ0DW£D§XHsŠ ŲDWADW‹DWĆDX`DW.DW%DWŽDW£. . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrČ0HrćÓlHsnHØHsŠ ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081935100819351008AVACCINATIONS 2021-02-25 menactra vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW@ B.. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB... VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŅ<HrĢ^¼DW*DČ(Hrź§(DWEDWE..DW.DW*... . . A@Phase 3DWFNNAš12-15 YearsA12-15 YearsAHrĢ^¼Hrź§(..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091205100912051009AVACCINATIONS 2021-01-15 Tdap Vaccine DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DW B]. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids B].. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D¶XHrX>ŲDVŃDėŒHruu DVķDW€..DV».DVŃ... . . A@Phase 3DW„NNAš12-15 YearsA12-15 YearsAHrX>ŲHruu ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DVķ B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B3.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»D¼pHrXDšDW\DįxHs,«xDVķDW<DWyDXDV».DVŃDWHDW\. . . A@Phase 3DW=NNAš12-15 YearsA12-15 YearsAHrXDšHru˜HsDHs,«xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DVķ B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B3.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»D¼pHrXDšDW\DįxHs,«xDVķDW<DWyDXDV».DVŃDWHDW\. . . A@Phase 3DW=NNAš12-15 YearsA12-15 YearsAHrXDšHru˜HsDHs,«xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DVķ B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B3.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»D¼pHrXDšDW\DįxHs,«xDVķDW<DWyDXDV».DVŃDWHDW\. . . A@Phase 3DW=NNAš12-15 YearsA12-15 YearsAHrXDšHru˜HsDHs,«xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVé B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B... VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV¼DØHHrY‚HDVŃD£˜Hru-DVķDW‡..DV¼.DVŃ... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrY‚HHru-..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVé B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B... VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV¼DØHHrY‚HDVŃD£˜Hru-DVķDW‡..DV¼.DVŃ... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrY‚HHru-..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVé B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B... VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV¼DØHHrY‚HDVŃD£˜Hru-DVķDW‡..DV¼.DVŃ... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrY‚HHru-..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DVš B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DVš B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DVš B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DVš B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DVš B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DVš B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B/.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĀDįxHra¤xDW§DŽ0Hsˆ°DV÷DW„DWÅDXdDVĀ.DVÕDW’DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHra¤xHrzµäHssŚŌHsˆ°Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVšDžLHržfLDW“Dę(Hs “(DW$DWDW×DXqDVš.DWDW DW“. . . A@Phase 3DW€NNAš12-15 YearsA12-15 YearsAHržfLHr¹äHs†køHs “(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DVß Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDĆHr ĪDW§D“xHs^ųDW!DWDWŹDXdDVņ.DWDW‘DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr ĪHr¹DHsr–8Hs^ųPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DVß Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDĆHr ĪDW§D“xHs^ųDW!DWDWŹDXdDVņ.DWDW‘DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr ĪHr¹DHsr–8Hs^ųPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DVß Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDĆHr ĪDW§D“xHs^ųDW!DWDWŹDXdDVņ.DWDW‘DW§. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr ĪHr¹DHsr–8Hs^ųPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Bd.. FOLLOW-UP WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVžDß Hr°¼ DWīDėŒHsķ0ŒDW6DWÉDXDX«DVž.DWDW×DWī. . . A@Phase 3DWŅNNAą12-15 YearsA12-15 YearsAHr°¼ HrĶoŒHsĪ±üHsķ0ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Bd.. FOLLOW-UP WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVžDß Hr°¼ DWīDėŒHsķ0ŒDW6DWÉDXDX«DVž.DWDW×DWī. . . A@Phase 3DWŅNNAą12-15 YearsA12-15 YearsAHr°¼ HrĶoŒHsĪ±üHsķ0ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Bd.. FOLLOW-UP WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVžDß Hr°¼ DWīDėŒHsķ0ŒDW6DWÉDXDX«DVž.DWDW×DWī. . . A@Phase 3DWŅNNAą12-15 YearsA12-15 YearsAHr°¼ HrĶoŒHsĪ±üHsķ0ŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1013 10131839101318391013AVACCINATIONS 2021-07-02 PFIZER BIONTECH COVID 19 VACCINE TOZINAMERAN 15268625001 YY DWæ BÕ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BÕ.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDŗTHr—ŠŌDWDŠ Hr³P DWDW½..DVė.DW... . . A@Phase 3DW¾NNAą12-15 YearsA12-15 YearsAHr—ŠŌHr³P ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»DŌ”HrX]DVĻD„0Hrrj°DVėDW..DV».DVĻ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX]Hrrj°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»DŌ”HrX]DVĻD„0Hrrj°DVėDW..DV».DVĻ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX]Hrrj°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»DŌ”HrX]DVĻD„0Hrrj°DVėDW..DV».DVĻ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX]Hrrj°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV± Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮDœTHr` ŌDVŌDŽ€Hry €DVńDW„..DVĮ.DVŌ... . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr` ŌHry €..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV± Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮDœTHr` ŌDVŌDŽ€Hry €DVńDW„..DVĮ.DVŌ... . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr` ŌHry €..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV± Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮDœTHr` ŌDVŌDŽ€Hry €DVńDW„..DVĮ.DVŌ... . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr` ŌHry €..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161334101613341016AVACCINATIONS 2020-09-12 flumist INFLUENZA VACCINE LIVE REASSORT 3V 01389809001Y DVš Ā'. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE LIVE REASSORT 3V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā'.. SCREENING WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDŅ“Hr`D4DW®D‡“Hs˜l“DVóDW‡DWĖDXkDVĮ.DVÖDW›DW®. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr`D4Hr|\Hsæ\Hs˜l“Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV  Ā!. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā!.. SCREENING WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDčDHr`YÄDWŠDęÜHsiUÜDVņDWXDW§DXGDVĮ.DVÕDWuDWŠ. . . A@Phase 3DWYNNAš12-15 YearsA12-15 YearsAHr`YÄHrzµ0HsM¤HsiUÜPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV  Ā!. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā!.. SCREENING WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDčDHr`YÄDWŠDęÜHsiUÜDVņDWXDW§DXGDVĮ.DVÕDWuDWŠ. . . A@Phase 3DWYNNAš12-15 YearsA12-15 YearsAHr`YÄHrzµ0HsM¤HsiUÜPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV  Ā!. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā!.. SCREENING WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDčDHr`YÄDWŠDęÜHsiUÜDVņDWXDW§DXGDVĮ.DVÕDWuDWŠ. . . A@Phase 3DWYNNAš12-15 YearsA12-15 YearsAHr`YÄHrzµ0HsM¤HsiUÜPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016A VACCINATIONS 2021-03-19 menactra MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DWV B–. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB–.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDčDHr`YÄDWŠDęÜHsiUÜDVņDWXDW§DXGDVĮ.DVÕDWuDWŠ. . . A@Phase 3DWYNNAš12-15 YearsA12-15 YearsAHr`YÄHrzµ0HsM¤HsiUÜPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1016 10161337101613371016A0VACCINATIONS 2021-03-19 trumenba MENINGOCOCCAL VACCINE B RFHBPA/FHBPB 06559313001 YY DWV B–. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBPA/FHBPB JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B–.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDčDHr`YÄDWŠDęÜHsiUÜDVņDWXDW§DXGDVĮ.DVÕDWuDWŠ. . . A@Phase 3DWYNNAš12-15 YearsA12-15 YearsAHr`YÄHrzµ0HsM¤HsiUÜPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1016 10161343101613431016AVACCINATIONS 2020-09-21 flucelvax quadrivalent INFLUENZA VACCINE INACT SAG 4V 01389812001Y DV£ Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SAG 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĀDź$Hra­$DVŲDĘĄHr~ŠĄDVōDW‹..DVĀ.DVŲ... . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHra­$Hr~ŠĄ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1039 10391295103912951039AVACCINATIONS 2021-07-26 Bexsero (Meningococcal B vaccine) MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV 06559314001 YY DW× BŅ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine BŅ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDxHrŗįDWD§ŠHrÖĄPDW>DW‹..DW.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHrŗįHrÖĄP..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391295103912951039A VACCINATIONS 2021-07-26 Menactra (Meningococcal conjugate) MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW× BŅ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBŅ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDxHrŗįDWD§ŠHrÖĄPDW>DW‹..DW.DW... . . A@Phase 3DWŒNNAŠ12-15 YearsA12-15 YearsAHrŗįHrÖĄP..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391297103912971039AVACCINATIONS 2021-04-30 gardasil, 0.5 mL, once, intramuscular HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW€ B{. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B{.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD‡xHrŗšxDWDkHrփœDW=DWŒ..DW.DW... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrŗšxHrփœ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW· B². .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B².. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDŖ(Hr»(DWDsPHrŁ.ŠDW=DW‹..DW.DW... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHr»(HrŁ.Š..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391317103913171039AVACCINATIONS 2021-03-04 Gardasil Vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DWG B9. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B9.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDĤHrĒ $DW¢DrœHsˆ…œDWADWŒDW¾DX_DW.DW$DWŽDW¢. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrĒ $Hrā“PHsnŠüHsˆ…œPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1039 10391320103913201039AVACCINATIONS 2021-05-17 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW‘ B‚. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‚.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD‘HrČ)DW%D’Hr棄DWADW‹..DW.DW%... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrČ)Hr棄..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391320103913201039A VACCINATIONS 2021-06-13 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW¬ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD‘HrČ)DW%D’Hr棄DWADW‹..DW.DW%... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrČ)Hr棄..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391327103913271039AVACCINATIONS 2021-05-15 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW B}. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B}.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDø°HrĢE0DW(DzŠHrē¶ŠDWEDWŒ..DW.DW(... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrĢE0Hrē¶Š..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391327103913271039A VACCINATIONS 2021-06-05 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW¤ B’. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B’.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDø°HrĢE0DW(DzŠHrē¶ŠDWEDWŒ..DW.DW(... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrĢE0Hrē¶Š..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441271104412711044AVACCINATIONS 2021-06-14 Pfizer Covid 19 Vaccine TOZINAMERAN 15268625001 YY DW­ B½. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B½.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVńD’xHrŸøųDWDŲĢHr¹šLDW%DWŒ..DVń.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrŸøųHr¹šL..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441271104412711044A VACCINATIONS 2021-05-24 Pfizer Covid 19 Vaccine( Non Study) TOZINAMERAN 15268625001 YY DW˜ BØ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BØ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVńD’xHrŸøųDWDŲĢHr¹šLDW%DWŒ..DVń.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrŸøųHr¹šL..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441290104412901044AVACCINATIONS 2020-11-23 GARDASIL HPV VACCINE VLP RL1 4V (YEAST) 06788703001Y DVā Ā.. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Ā... SCREENING WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĀÄHrČZÄDW%DĆšHrä pDWADW..DW.DW%... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrČZÄHrä p..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DVā Ā.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā... SCREENING WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĀÄHrČZÄDW%DĆšHrä pDWADW..DW.DW%... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrČZÄHrä p..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DVā Ā.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā... SCREENING WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĀÄHrČZÄDW%DĆšHrä pDWADW..DW.DW%... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrČZÄHrä p..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DVā Ā.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā... SCREENING WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDĀÄHrČZÄDW%DĆšHrä pDWADW..DW.DW%... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHrČZÄHrä p..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441293104412931044AVACCINATIONS 2021-06-04 Pfizer Covid 19 vaccine TOZINAMERAN 15268625001 Y YDW£ BŖ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŖ.. OPEN LABEL TREATMENTWHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVśE7@Hr«štDWŽDēHsnœDW+DWŒDWČDXbDVś.DW DWŽ.. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr«štHrē€HsnœHsnœPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1044 10441294104412941044AVACCINATIONS 2021-06-04 Pfizer Covid 19 Vaccine TOZINAMERAN 15268625001 Y YDW£ BŖ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŖ.. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVśE;Hr«š°DWŽDēTHsnœTDW+DWŒDWæDXbDVś.DW DWŽ.. . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr«š°HrēDHsnœTHsnœTPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1044 10441356104413561044AVACCINATIONS 2021-05-14 non-study COVID-19 Pfizer vaccine TOZINAMERAN 15268625001 YY DWŽ B}. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B}.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD£˜HrŹŽ˜DW)DōģHré‚lDWKDWŚ..DW.DW)... . . A@Phase 3.NNAĄ12-15 YearsA12-15 YearsAHrŹŽ˜Hré‚l..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1044 10441356104413561044A VACCINATIONS 2021-06-04 non-study COVID-19 Pfizer vaccines TOZINAMERAN 15268625001 YY DW£ B’. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B’.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD£˜HrŹŽ˜DW)DōģHré‚lDWKDWŚ..DW.DW)... . . A@Phase 3.NNAĄ12-15 YearsA12-15 YearsAHrŹŽ˜Hré‚l..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1057 10571389105713891057AVACCINATIONS 2021-06-12 PFIZER BNT162B2 TOZINAMERAN 15268625001 YY DW« Bŗ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bŗ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDĖ4Hr Ö4DW DźŲHrĆ<ŲDW*DWŒ..DVņ.DW ... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr Ö4HrĆ<Ų..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1057 10571389105713891057A VACCINATIONS 2021-05-23 PFIZER BNT162b2 TOZINAMERAN 15268625001 YY DW— B¦. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¦.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDĖ4Hr Ö4DW DźŲHrĆ<ŲDW*DWŒ..DVņ.DW ... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr Ö4HrĆ<Ų..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DVć Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Įš.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDž4Hr ©4DW®D¾Hs˜£DW#DWDWĢDXkDVņ.DWDW’DW®. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr ©4Hr¼]dHssq\Hs˜£Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DVć Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Įš.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDž4Hr ©4DW®D¾Hs˜£DW#DWDWĢDXkDVņ.DWDW’DW®. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr ©4Hr¼]dHssq\Hs˜£Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DVć Įš. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Įš.. SCREENING WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVņDž4Hr ©4DW®D¾Hs˜£DW#DWDWĢDXkDVņ.DWDW’DW®. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHr ©4Hr¼]dHssq\Hs˜£Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1077 10771282107712821077AVACCINATIONS 2021-05-15 PFIZER COVID-19 VACCINE TOZINAMERAN 15268625001 YY DW B™. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B™.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷DššHr§“pDW Dč¼HrČ<DW+DWŒ..DV÷.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr§“pHrČ<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1077 10771289107712891077AVACCINATIONS 2021-05-14 PFIZER BNT162b2 COVID-19 VACCINE TOZINAMERAN 15268625001 YY DWŽ B”. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B”.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVūDŌHr¬¼œDWDĶPHrČePDW3DWŒ..DVū.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¬¼œHrČeP..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1077 10771290107712901077AVACCINATIONS 2021-05-14 PFIZER BNT162b2 COVID-19 VACCINE TOZINAMERAN 15268625001 YY DWŽ B”. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B”.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVūDŌXHr¬¼ŲDWDĶČHrČeČDW3DW..DVū.DW... . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHr¬¼ŲHrČeČ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841542108415421084AVACCINATIONS 2021-05-18 Pfizer-BioNTech COVID-19 vaccine TOZINAMERAN 15268625001 YY DW’ BŸ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŸ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVōD©ģHr£WģDWDŁųHr¼”xDW%DWŒ..DVō.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr£WģHr¼”x..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841542108415421084A VACCINATIONS 2021-06-08 Pfizer-BioNTech COVID-19 vaccine TOZINAMERAN 15268625001 YY DW§ B“. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B“.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVōD©ģHr£WģDWDŁųHr¼”xDW%DWŒ..DVō.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr£WģHr¼”x..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW‡ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDėHr¼„”DWąDöHsŚĘDW=DWŒDWüDXDW.DWDW•DWą. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841579108415791084AVACCINATIONS 2021-05-14 Pfizer Covid-19 Vaccination TOZINAMERAN 15268625001 YY DWŽ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDČÜHrŽÜDW#Dš<Hrį”¼DW@DWŒ..DW.DW#... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrŽÜHrį”¼..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDWø BĪ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated BĪ.. OPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVėDäHHr—“ČDW D›(Hs† (DWDW…DW¾DX]DVė.DVžDWŒDW . . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr—“ČHr°·4Hsk–äHs† (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911413109114131091AVACCINATIONS 2021-06-28 Gardasil vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW» BŹ. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BŹ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVņDä Hr ļ DWD»€HrĒDW0DW—..DVņ.DW... . . A@Phase 3DW˜NNAĄ12-15 YearsA12-15 YearsAHr ļ HrĒ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BE.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVśDģøHr«ƒøDWDėHrĒ1”DW+DW‘..DVś.DW... . . A@Phase 3DW’NNAĄ12-15 YearsA12-15 YearsAHr«ƒøHrĒ1”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) BE.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVśDģøHr«ƒøDWDėHrĒ1”DW+DW‘..DVś.DW... . . A@Phase 3DW’NNAĄ12-15 YearsA12-15 YearsAHr«ƒøHrĒ1”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) BE.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVśDģøHr«ƒøDWDėHrĒ1”DW+DW‘..DVś.DW... . . A@Phase 3DW’NNAĄ12-15 YearsA12-15 YearsAHr«ƒøHrĒ1”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911443109114431091AVACCINATIONS 2021-08-04 Tdap vaccine DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DWą Bć. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids Bć.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVžDÖ8Hr°³8DWD¼HrŃR<DW3DW..DVž.DW... . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHr°³8HrŃR<..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911455109114551091AVACCINATIONS 2021-05-13 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW Bˆ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bˆ.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD•ˆHrŗžˆDWDœHr֚DWADWŒ..DW.DW... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrŗžˆHr֚..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911455109114551091A VACCINATIONS 2021-06-03 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW¢ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD•ˆHrŗžˆDWDœHr֚DWADWŒ..DW.DW... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrŗžˆHr֚..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911456109114561091AVACCINATIONS 2021-05-13 Pfizer covid-19 vaccine TOZINAMERAN 15268625001 YY DW Bˆ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bˆ.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDķ0Hr»V0DWDĶHrՔDW6DWŒ..DW.DW... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHr»V0HrՔ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911456109114561091A VACCINATIONS 2021-06-03 Pfizer covid-19 vaccine TOZINAMERAN 15268625001 YY DW¢ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDķ0Hr»V0DWDĶHrՔDW6DWŒ..DW.DW... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHr»V0HrՔ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911461109114611091AVACCINATIONS 2021-05-19 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW“ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWD¬€Hr¼gDWDÉTHrÖįŌDW8DWŒ..DW.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¼gHrÖįŌ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911461109114611091A VACCINATIONS 2021-06-09 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DWØ B¢. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¢.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWD¬€Hr¼gDWDÉTHrÖįŌDW8DWŒ..DW.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¼gHrÖįŌ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BY.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷D†ˆHr§)DW­DŖ Hs—> DW(DWŒDWÉDXjDV÷.DW DW“DW­. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr§)HrĀÓ`Hsu€Hs—> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) BY.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷D†ˆHr§)DW­DŖ Hs—> DW(DWŒDWÉDXjDV÷.DW DW“DW­. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr§)HrĀÓ`Hsu€Hs—> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) BY.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV÷D†ˆHr§)DW­DŖ Hs—> DW(DWŒDWÉDXjDV÷.DW DW“DW­. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr§)HrĀÓ`Hsu€Hs—> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261281112612811126AVACCINATIONS 2021-02-12 Fluarix Quadrivalent Influenza Vaccination INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW3 B;. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B;.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVłD¤ÄHr©źDDWDędHrĒ,äDW3DWŒ..DVł.DW... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr©źDHrĒ,ä..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Bg.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVśDóüHr«ŠüDW¦D¢ØHsūØDW+DWŒDWÅDXcDVś.DWDW‘DW¦. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr«ŠüHrĒ+|Hsrf¤HsūØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Bg.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVśDóüHr«ŠüDW¦D¢ØHsūØDW+DWŒDWÅDXcDVś.DWDW‘DW¦. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr«ŠüHrĒ+|Hsrf¤HsūØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Bg.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVśDóüHr«ŠüDW¦D¢ØHsūØDW+DWŒDWÅDXcDVś.DWDW‘DW¦. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHr«ŠüHrĒ+|Hsrf¤HsūØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Ba.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDķäHrĒ4dDW§DʄHsqDW@DWŒDWĆDXdDW.DW$DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrĒ4dHrā±DHssĖ HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Ba.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDķäHrĒ4dDW§DʄHsqDW@DWŒDWĆDXdDW.DW$DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrĒ4dHrā±DHssĖ HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Ba.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDķäHrĒ4dDW§DʄHsqDW@DWŒDWĆDXdDW.DW$DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrĒ4dHrā±DHssĖ HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B6.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDõÜHrȍÜDW§DĒ°Hsr0DWEDWŒDWĆDXdDW.DW%DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrȍÜHrä+PHssĮHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B6.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDõÜHrȍÜDW§DĒ°Hsr0DWEDWŒDWĆDXdDW.DW%DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrȍÜHrä+PHssĮHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B6.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDõÜHrȍÜDW§DĒ°Hsr0DWEDWŒDWĆDXdDW.DW%DW’DW§. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrȍÜHrä+PHssĮHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW÷ C°. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated C°.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVķDž¬Hrš,DWD­¬Hr³-¬DWDW..DVķ.DW... . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHrš,Hr³-¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW÷ C°. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen C°.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVķDž¬Hrš,DWD­¬Hr³-¬DWDW..DVķ.DW... . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHrš,Hr³-¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW÷ C°. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus C°.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVķDž¬Hrš,DWD­¬Hr³-¬DWDW..DVķ.DW... . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHrš,Hr³-¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391166113911661139AVACCINATIONS 2021-07-20 menactra MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 Y YDWŃ BŽ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBŽ.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVōDāhHr£hDWND»DHsDDW.DW.DWpDX DVō.DWDW7DWN. . . A@Phase 3DW/NNAš12-15 YearsA12-15 YearsAHr£hHr¼†ąHrū“(HsDPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1139 11391169113911691139AVACCINATIONS 2021-05-11 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW‹ B”. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B”.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVųD¼Hrؑ¼DWD¶”HrŠ7”DW8DWŒ..DVų.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrؑ¼HrŠ7”..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1139 11391169113911691139A VACCINATIONS 2021-06-01 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW  B©. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B©.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVųD¼Hrؑ¼DWD¶”HrŠ7”DW8DWŒ..DVų.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrؑ¼HrŠ7”..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391171113911711139AVACCINATIONS 2021-05-19 Pfizer, COVID-19 vaccine TOZINAMERAN 15268625001 YY DW“ Bœ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bœ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVųD PHrؔPDW D²ŌHrÄVTDWMDWŒ..DVų.DW ... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrؔPHrÄVT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391171113911711139A VACCINATIONS 2021-06-09 Pfizer, COVID-19 vaccine TOZINAMERAN 15268625001 YY DWØ B±. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B±.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVųD PHrؔPDW D²ŌHrÄVTDWMDWŒ..DVų.DW ... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrؔPHrÄVT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391235113912351139AVACCINATIONS 2021-07-07 Menactra vaccine MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 Y YDWÄ Bø. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBø.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DģHrď„DWKD³HsDW.DW.DWgDXDW .DW$DW6DWK. . . A@Phase 3DW/NNAš12-15 YearsA12-15 YearsAHrď„HrāŹXHrś‹¬HsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DWĻ BŠDWÜ BŻ PREDNISONE AALIMENTARY TRACT AND METABOLISM A07ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTSA07EINTESTINAL ANTIINFLAMMATORY AGENTS A07EACORTICOSTEROIDS ACTING LOCALLYA07EA03prednisone BŠBŻBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD‹°Hr³ °DWDŃHrĻDW9DW…..DW.DW... . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr³ °HrĻ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DWĻ BŠDWÜ BŻ PREDNISONE HSYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSH02CORTICOSTEROIDS FOR SYSTEMIC USE H02ACORTICOSTEROIDS FOR SYSTEMIC USE, PLAINH02ABGLUCOCORTICOIDS H02AB07prednisone BŠBŻBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD‹°Hr³ °DWDŃHrĻDW9DW…..DW.DW... . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr³ °HrĻ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DWĻ BŠDWÜ BŻ PREDNISONE SSENSORY ORGANS S01OPHTHALMOLOGICALS S01BANTIINFLAMMATORY AGENTS S01BACORTICOSTEROIDS, PLAIN BŠBŻBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD‹°Hr³ °DWDŃHrĻDW9DW…..DW.DW... . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr³ °HrĻ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DWĻ BŠDWÜ BŻ PREDNISONE DDERMATOLOGICALS D07CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07ACORTICOSTEROIDS, PLAIN BŠBŻBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD‹°Hr³ °DWDŃHrĻDW9DW…..DW.DW... . . A@Phase 3DW†NNAš12-15 YearsA12-15 YearsAHr³ °HrĻ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401357114013571140AVACCINATIONS 2021-05-13 Pfizer COVID-19 Vaccine Dose 1 TOZINAMERAN 15268625001 YY DW BŽ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŽ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDʄHr³F„DWDŅxHrĢ^ųDW/DWŒ..DW.DW... . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHr³F„HrĢ^ų..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõDĆ“Hr¤Ć4DW DŸ`HrĀń`DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHr¤Ć4HrĀń`..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõDĆ“Hr¤Ć4DW DŸ`HrĀń`DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHr¤Ć4HrĀń`..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõDĆ“Hr¤Ć4DW DŸ`HrĀń`DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHr¤Ć4HrĀń`..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated Ā.. SCREENING WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõD€¬Hr¤€,DW D’|HrĀä|DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¤€,HrĀä|..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõD€¬Hr¤€,DW D’|HrĀä|DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¤€,HrĀä|..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DVā Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus Ā.. SCREENING WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVõD€¬Hr¤€,DW D’|HrĀä|DW-DWŒ..DVõ.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr¤€,HrĀä|..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĆšHr›ˆšDWVD‚Hs$cDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›ˆšHr¹×8Hs…Hs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDÄhHr›‰hDWVDƒ@Hs$d@DW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›‰hHr¹Ų Hs„˜Hs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDWš B­. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B­.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVīDĮ˜Hr›†˜DWVDƒōHs$dōDW&DW7DWuDXDVī.DWDW?DWV. . . A@Phase 3DW8NNAš12-15 YearsA12-15 YearsAHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471284114712841147AVACCINATIONS 2021-05-30 BNT162b2 0.3mL IM TOZINAMERAN 15268625001 YY DWž BŖ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŖ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVõD§Hr¤¦œDW DɐHrƐDW-DW‹..DVõ.DW ... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¤¦œHrƐ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471284114712841147A VACCINATIONS 2021-06-23 BNT162b2 0.3mL IM TOZINAMERAN 15268625001 YY DW¶ BĀ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĀ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVõD§Hr¤¦œDW DɐHrƐDW-DW‹..DVõ.DW ... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHr¤¦œHrƐ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471322114713221147AVACCINATIONS 2021-05-14 Non-study COVID-19 Vaccine (Pfizer) TOZINAMERAN 15268625001 YY DWŽ B‚. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‚.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠŌHrÄtTDW#DƒHrį'„DWKDW‹..DW .DW#... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÄtTHrį'„..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471322114713221147A VACCINATIONS 2021-06-04 Non-study COVID-19 vaccine (Pfizer) TOZINAMERAN 15268625001 YY DW£ B—. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B—.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DŠŌHrÄtTDW#DƒHrį'„DWKDW‹..DW .DW#... . . A@Phase 3DWŒNNAĄ12-15 YearsA12-15 YearsAHrÄtTHrį'„..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471323114713231147AVACCINATIONS 2021-05-14 Non-study COVID-19 Vaccine (Pfizer) TOZINAMERAN 15268625001 YY DWŽ B‚. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‚.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DędHrĉäDW#Dš“Hrį•4DW@DW‹..DW .DW#... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrĉäHrį•4..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471323114713231147A VACCINATIONS 2021-06-04 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW£ B—. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B—.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DędHrĉäDW#Dš“Hrį•4DW@DW‹..DW .DW#... . . A@Phase 3DWŒNNAą12-15 YearsA12-15 YearsAHrĉäHrį•4..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471327114713271147AVACCINATIONS 2021-05-07 BNT162b2 Dose #1 IM/once TOZINAMERAN 15268625001 YY DW‡ B{. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B{.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DńhHrĔčDW DńhHrĔčDW@DWŒ..DW ..... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrĔčHrĔč..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0AC4591001C4591001 1147 11471327114713271147A VACCINATIONS 2021-06-04 BNT162b2 Dose #2 IM/once TOZINAMERAN 15268625001 YY DW£ B—. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B—.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DńhHrĔčDW DńhHrĔčDW@DWŒ..DW ..... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrĔčHrĔč..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYAfter unblinding and before Vaccination 3A@AC4591001C4591001 1147 11471335114713351147AVACCINATIONS 2021-05-20 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW” B‡. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‡.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD”ōHrŖōDW#D¼Hrį$<DW@DW‹..DW.DW#... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrŖōHrį$<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471335114713351147A VACCINATIONS 2021-06-10 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW© Bœ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES Bœ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD”ōHrŖōDW#D¼Hrį$<DW@DW‹..DW.DW#... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrŖōHrį$<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471336114713361147AVACCINATIONS 2021-07-22 BNT162B2 0.3 mL IM TOZINAMERAN 15268625001 YY DWÓ BĘ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĘ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD³HrÅØDW#D”@HrįEĄDW@DW‹..DW.DW#... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrÅØHrįEĄ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471336114713361147A VACCINATIONS 2021-08-12 BNT162B2 0.3 mL IM TOZINAMERAN 15268625001 YY DWč BŪ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BŪ.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD³HrÅØDW#D”@HrįEĄDW@DW‹..DW.DW#... . . A@Phase 3DWŒNNAš12-15 YearsA12-15 YearsAHrÅØHrįEĄ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DV­DĀa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated ... WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDöHrÅėDW3DķäHröŖdDWODWŒ..DW.DW3... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrÅėHröŖd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DV­DĀa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen ... WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDöHrÅėDW3DķäHröŖdDWODWŒ..DW.DW3... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrÅėHröŖd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DV­DĀa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus ... WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDöHrÅėDW3DķäHröŖdDWODWŒ..DW.DW3... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrÅėHröŖd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147A VACCINATIONS 2021-01-13 Gardasil HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW A€. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) A€.. VACCINATION WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDöHrÅėDW3DķäHröŖdDWODWŒ..DW.DW3... . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrÅėHröŖd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D‚PHrX ŠDVĪDśHrqDVėDW‹..DV».DVĪ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX ŠHrq..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D‚PHrX ŠDVĪDśHrqDVėDW‹..DV».DVĪ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX ŠHrq..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D‚PHrX ŠDVĪDśHrqDVėDW‹..DV».DVĪ... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrX ŠHrq..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVģ B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B2.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D¤ÄHrX-DDVŠDĒ°Hrs’°DVģDWŒ..DV».DVŠ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrX-DHrs’°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVģ B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B2.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D¤ÄHrX-DDVŠDĒ°Hrs’°DVģDWŒ..DV».DVŠ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrX-DHrs’°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVģ B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B2.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DV»D¤ÄHrX-DDVŠDĒ°Hrs’°DVģDWŒ..DV».DVŠ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrX-DHrs’°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»Dé4HrXq“DW©DņXHs’?ŲDVėDW‹DWÉDXfDV».DVĪDW”DW©. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrXq“Hrq,ąHsv6Hs’?ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»Dé4HrXq“DW©DņXHs’?ŲDVėDW‹DWÉDXfDV».DVĪDW”DW©. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrXq“Hrq,ąHsv6Hs’?ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DVė B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV»Dé4HrXq“DW©DņXHs’?ŲDVėDW‹DWÉDXfDV».DVĪDW”DW©. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrXq“Hrq,ąHsv6Hs’?ŲPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B5.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĄD÷Hr_DWRDƒōHsōDVōDW6DWnDXDVĄ.DVŌDW>DWR. . . A@Phase 3DW7NNAš12-15 YearsA12-15 YearsAHr_Hry HsŻPHsōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B5.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĄD÷Hr_DWRDƒōHsōDVōDW6DWnDXDVĄ.DVŌDW>DWR. . . A@Phase 3DW7NNAš12-15 YearsA12-15 YearsAHr_Hry HsŻPHsōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B5.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĄD÷Hr_DWRDƒōHsōDVōDW6DWnDXDVĄ.DVŌDW>DWR. . . A@Phase 3DW7NNAš12-15 YearsA12-15 YearsAHr_Hry HsŻPHsōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B5.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄDöĢHr_ĢDVŌDŠ Hry DVōDWŒ..DVĄ.DVŌ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr_ĢHry ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B5.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄDöĢHr_ĢDVŌDŠ Hry DVōDWŒ..DVĄ.DVŌ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr_ĢHry ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DVō B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B5.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄDöĢHr_ĢDVŌDŠ Hry DVōDWŒ..DVĄ.DVŌ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr_ĢHry ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVń B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮD‡šHr_łpDVÕDĄäHrzdDVńDW1..DVĮ.DVÕ... . . A@Phase 3DW2NNAš12-15 YearsA12-15 YearsAHr_łpHrzd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVń B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮD‡šHr_łpDVÕDĄäHrzdDVńDW1..DVĮ.DVÕ... . . A@Phase 3DW2NNAš12-15 YearsA12-15 YearsAHr_łpHrzd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DVń B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĮD‡šHr_łpDVÕDĄäHrzdDVńDW1..DVĮ.DVÕ... . . A@Phase 3DW2NNAš12-15 YearsA12-15 YearsAHr_łpHrzd..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501171115011711150AVACCINATIONS 2021-09-01 Pfizer BNT162b2 Comirnaty COVID-19 Vaccine TOZINAMERAN 15268625001 YY DWü C. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES C.. REPEAT SCREENING 1 WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVģD‰”Hr˜«”DWD˜XHr“iŲDW!DWŒ..DVģ.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr˜«”Hr“iŲ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1150 11501178115011781150AVACCINATIONS 2021-02-22 Gardasil Vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW= BN. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BN.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVšD²\Hrž\DWDõdHrŗ äDW"DWŒ..DVš.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrž\Hrŗ ä..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVšD²\Hrž\DWDõdHrŗ äDW"DWŒ..DVš.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrž\Hrŗ ä..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVšD²\Hrž\DWDõdHrŗ äDW"DWŒ..DVš.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrž\Hrŗ ä..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVšD²\Hrž\DWDõdHrŗ äDW"DWŒ..DVš.DW... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrž\Hrŗ ä..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B4.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVųDżŌHrØńŌDW D¾ŒHrĆŒDW+DWŒ..DVų.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrØńŌHrĆŒ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B4.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVųDżŌHrØńŌDW D¾ŒHrĆŒDW+DWŒ..DVų.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrØńŌHrĆŒ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B4.. FOLLOW-UP WHODDG B3 v202103AąYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVųDżŌHrØńŌDW D¾ŒHrĆŒDW+DWŒ..DVų.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHrØńŌHrĆŒ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B2.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW D‚ČHrÄ&HDW"Dz”HrßĶ”DW?DWŒ..DW .DW"... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrÄ&HHrßĶ”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B2.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW D‚ČHrÄ&HDW"Dz”HrßĶ”DW?DWŒ..DW .DW"... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrÄ&HHrßĶ”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B2.. VACCINATION WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW D‚ČHrÄ&HDW"Dz”HrßĶ”DW?DWŒ..DW .DW"... . . A@Phase 3DWNNAŠ12-15 YearsA12-15 YearsAHrÄ&HHrßĶ”..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedAP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated AP.. VACCINATION WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD§ŠHrĢ4PDW3DĪōHrö‹tDWCDWC..DW.DW3... . . A@Phase 3DWDNNAš12-15 YearsA12-15 YearsAHrĢ4PHrö‹t..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1152 11521698115216981152AVACCINATIONS 2021-05-15 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B•. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B•.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVūDŁųHr¬ĀxDWDÉTHrČaTDW/DW..DVū.DW... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHr¬ĀxHrČaT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521726115217261152AVACCINATIONS 2021-06-12 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW« B„. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B„.. REPEAT SCREENING 1 WHODDG B3 v202103AĄYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDł`Hr¼³ąDWDā,HrÕ©,DW6DW§..DW.DW... . . A@Phase 3DWØNNAĄ12-15 YearsA12-15 YearsAHr¼³ąHrÕ©,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521747115217471152AVACCINATIONS 2021-07-20 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 Y YDWŃ BĀ. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES BĀ.. OPEN LABEL TREATMENTWHODDG B3 v202103AąYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDģōHrȄōDW”DąHsv~DWKDWDWĪDXhDW.DW#DW”.. . . A@Phase 3DWŽNNAą12-15 YearsA12-15 YearsAHrȄōHrį^\Hsv~Hsv~Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA0C4591001C4591001 1152 11521751115217511152AVACCINATIONS 2021-05-17 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW‘ B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|°HrĢ 0DW)D€Hré DWEDW..DW.DW)... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHrĢ 0Hré ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521754115217541152AVACCINATIONS 2021-05-20 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW” B‚. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B‚.. REPEAT SCREENING 1 WHODDG B3 v202103AŠYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDėČHrĢxHDW(DćŠHrčŠDWDDW..DW.DW(... . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHrĢxHHrčŠ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV„ Ā. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Ā.. SCREENING WHODDG B3 v202103AąYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVĀDŠŌHra“ŌDWŖDėPHs“ŠPDVńDWDWÅDXgDVĀ.DVÕDW•DWŖ. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHra“ŌHrziøHsw•4Hs“ŠPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV„ Ā. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Ā.. SCREENING WHODDG B3 v202103AąYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVĀDŠŌHra“ŌDWŖDėPHs“ŠPDVńDWDWÅDXgDVĀ.DVÕDW•DWŖ. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHra“ŌHrziøHsw•4Hs“ŠPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV„ Ā. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Ā.. SCREENING WHODDG B3 v202103AąYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVĀDŠŌHra“ŌDWŖDėPHs“ŠPDVńDWDWÅDXgDVĀ.DVÕDW•DWŖ. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHra“ŌHrziøHsw•4Hs“ŠPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156A VACCINATIONS 2020-09-23 MEN B (BEXSERO) MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV 06559314001Y DV„ Ā. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine Ā.. SCREENING WHODDG B3 v202103AąYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVĀDŠŌHra“ŌDWŖDėPHs“ŠPDVńDWDWÅDXgDVĀ.DVÕDW•DWŖ. . . A@Phase 3DW‘NNAą12-15 YearsA12-15 YearsAHra“ŌHrziøHsw•4Hs“ŠPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BM.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄD¦ąHr^ĘąDV×DĻ0Hr}A°DVśDW“..DVĄ.DV×... . . A@Phase 3DW”NNAĄ12-15 YearsA12-15 YearsAHr^ĘąHr}A°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BM.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄD¦ąHr^ĘąDV×DĻ0Hr}A°DVśDW“..DVĄ.DV×... . . A@Phase 3DW”NNAĄ12-15 YearsA12-15 YearsAHr^ĘąHr}A°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BM.. FOLLOW-UP WHODDG B3 v202103AĄYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVĄD¦ąHr^ĘąDV×DĻ0Hr}A°DVśDW“..DVĄ.DV×... . . A@Phase 3DW”NNAĄ12-15 YearsA12-15 YearsAHr^ĘąHr}A°..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DWŠ BŹ. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen BŹ.. FOLLOW-UP WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVĮDÖģHr`HlDW­D”|Hs—4üDVńDWDWÉDXjDVĮ.DVÕDW™DW­. . . A@Phase 3DW‘NNAš12-15 YearsA12-15 YearsAHr`HlHrzhHs|×ģHs—4üPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DVń A€. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) A€.. VACCINATION WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVźDź$Hr–i$DWD•HrĘŪDW,DW”..DVź.DW... . . A@Phase 3DW¢NNAĄ12-15 YearsA12-15 YearsAHr–i$HrĘŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DVń A€. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) A€.. VACCINATION WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVźDź$Hr–i$DWD•HrĘŪDW,DW”..DVź.DW... . . A@Phase 3DW¢NNAĄ12-15 YearsA12-15 YearsAHr–i$HrĘŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DVń A€. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) A€.. VACCINATION WHODDG B3 v202103AĄYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVźDź$Hr–i$DWD•HrĘŪDW,DW”..DVź.DW... . . A@Phase 3DW¢NNAĄ12-15 YearsA12-15 YearsAHr–i$HrĘŪ..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561336115613361156AVACCINATIONS 2021-05-13 COVID-19 PFIZER VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV’D°Hr±Ž„DWD¦¤HrĢ3$DW3DW¦..DV’.DW... . . A@Phase 3DW§NNAš12-15 YearsA12-15 YearsAHr±Ž„HrĢ3$..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1156 11561336115613361156A VACCINATIONS 2021-06-03 COVID-19 PFIZER VACCINE TOZINAMERAN 15268625001 YY DW¢ B¤. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B¤.. FOLLOW-UP WHODDG B3 v202103AšYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DV’D°Hr±Ž„DWD¦¤HrĢ3$DW3DW¦..DV’.DW... . . A@Phase 3DW§NNAš12-15 YearsA12-15 YearsAHr±Ž„HrĢ3$..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW¤ B—. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B—.. REPEAT SCREENING 1 WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDī˜HrÅć˜DW"Dé¬Hrą<¬DW@DW—..DW.DW"... . . A@Phase 3DW˜NNAš12-15 YearsA12-15 YearsAHrÅć˜Hrą<¬..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561353115613531156AVACCINATIONS 2021-06-10 BNT162B2 COVID-19 PFIZER TOZINAMERAN 15268625001 Y YDW© B›. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B›.. OPEN LABEL TREATMENTWHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDߘHrĒ&DW‘DóHHsrœČDW?DWŒDWĘDXeDW.DW#DW‘.. . . A@Phase 3DWNNAĄ12-15 YearsA12-15 YearsAHrĒ&Hrį‡$HsrœČHsrœČPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1156 11561359115613591156AVACCINATIONS 2021 PFIZER COVID-19 VACCINE TOZINAMERAN 15268625001Y DW MĮp. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES ... WHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDštHrČ2tDWŽDƌHsndŒDWGDWŒDW½DXbDW.DW%DWŽ.. . . A@Phase 3DWNNAš12-15 YearsA12-15 YearsAHrČ2tHrćŪdHsndŒHsndŒPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW¬ Bœ. . PREDNISONE AALIMENTARY TRACT AND METABOLISM A07ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTSA07EINTESTINAL ANTIINFLAMMATORY AGENTS A07EACORTICOSTEROIDS ACTING LOCALLYA07EA03prednisone Bœ.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD’|HrÉ{üDW©DŒ(Hs‘ŁØDWFDW“DWĘDXfDW.DW%DW•DW©. . . A@Phase 3DW”NNAš12-15 YearsA12-15 YearsAHrÉ{üHrä"ąHsw© Hs‘ŁØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW¬ Bœ. . PREDNISONE HSYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSH02CORTICOSTEROIDS FOR SYSTEMIC USE H02ACORTICOSTEROIDS FOR SYSTEMIC USE, PLAINH02ABGLUCOCORTICOIDS H02AB07prednisone Bœ.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD’|HrÉ{üDW©DŒ(Hs‘ŁØDWFDW“DWĘDXfDW.DW%DW•DW©. . . A@Phase 3DW”NNAš12-15 YearsA12-15 YearsAHrÉ{üHrä"ąHsw© Hs‘ŁØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW¬ Bœ. . PREDNISONE SSENSORY ORGANS S01OPHTHALMOLOGICALS S01BANTIINFLAMMATORY AGENTS S01BACORTICOSTEROIDS, PLAIN Bœ.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD’|HrÉ{üDW©DŒ(Hs‘ŁØDWFDW“DWĘDXfDW.DW%DW•DW©. . . A@Phase 3DW”NNAš12-15 YearsA12-15 YearsAHrÉ{üHrä"ąHsw© Hs‘ŁØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW¬ Bœ. . PREDNISONE DDERMATOLOGICALS D07CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07ACORTICOSTEROIDS, PLAIN Bœ.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AšYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD’|HrÉ{üDW©DŒ(Hs‘ŁØDWFDW“DWĘDXfDW.DW%DW•DW©. . . A@Phase 3DW”NNAš12-15 YearsA12-15 YearsAHrÉ{üHrä"ąHsw© Hs‘ŁØPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1270 12701207127012071270AVACCINATIONS 2021-02-03 FLUARIX QUADRIVALENT (INFLUENZA VACCINE) INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW* B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B2.. FOLLOW-UP WHODDG B3 v202103AąYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVłD€pHr©ÅšDW DĆ<HrÄf¼DW*DWŒ..DVł.DW ... . . A@Phase 3DWNNAą12-15 YearsA12-15 YearsAHr©ÅšHrÄf¼..BNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€ . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1270 12701221127012211270AVACCINATIONS 2021-02-03 INFLUENZA VACCINE (FLUARIX QUADRIVALENT) INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW* B0. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B0.. FOLLOW-UP WHODDG B3 v202103AĄYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVūD““Hr¬4DW­DŌŠHs—hPDW*DWDWÉDXjDVū.DWDWšDW­. . . A@Phase 3DWŽNNAĄ12-15 YearsA12-15 YearsAHr¬4HrŚšHs~.ŠHs—hPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1270 12701237127012371270AVACCINATIONS 2020-12-21 Fluarix Quadrivalent (Influenza Vaccine) INFLUENZA VACCINE INACT SPLIT 4V 01389806001Y DVž Ā. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen Ā.. SCREENING WHODDG B3 v202103AŠYEARSFA AMERICAN INDIAN OR ALASKA NATIVEA0AMERICAN INDIAN OR ALASKA NATIVEA0YPlacebo PLACEBO Placebo PLACEBO DWDˆ¤HrĘĻ$DW“D‹tHst×ōDWZDWDWĶDXgDW..DW“.. . . A@Phase 3DWŽNNAŠ12-15 YearsA12-15 YearsAHrĘĻ$HrĘĻ$Hst×ōHst×ōPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)A€BNT162b2 Phase 2/3 (30 mcg)A€Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .